Abstract
Clinical trials are undergoing rapid transformation through the integration of artificial intelligence (AI), natural language processing (NLP), adaptive design methodologies, and remote patient monitoring technologies. While AI enhances efficiency in site selection, recruitment forecasting, prescreening, and real-world data integration, persistent inequities in representation and structural biases within health systems threaten the validity and fairness of trial outcomes.
This study develops a comprehensive theoretical framework synthesizing AI-driven operational optimization with equity-centered design principles in clinical trials. Drawing exclusively from contemporary literature on site selection algorithms, recruitment intelligence, electronic health record (EHR) mining, social determinants of health (SDOH) extraction, fairness in machine learning, and biomedical workforce diversity, the research conceptualizes an integrated model for equitable AI-enabled clinical trials.
A structured integrative review methodology was employed, synthesizing empirical studies, conceptual analyses, adaptive design research, and health equity scholarship. Thematic synthesis was conducted across six domains: AI-assisted site selection, competitive intelligence, recruitment optimization, EHR-based cohort identification, SDOH extraction, and ethical machine learning governance. Workforce diversity and large-scale population research initiatives were analyzed as contextual systems influencing AI deployment.
AI technologies demonstrate measurable advantages in optimizing site selection through metaheuristic algorithms, accelerating recruitment via NLP-driven screening, enabling adaptive trial redesign, and augmenting structured data with SDOH signals. However, implementation challenges-including electronic medical record system limitations, algorithmic bias, inequitable workforce representation, and restrictive eligibility criteria-introduce systemic risks. A multi-layered “Equity Engineering Framework” is proposed, integrating fairness auditing, adaptive inclusion recalibration, SDOH-informed cohort modeling, and AI-supported decentralized trial operations.
AI must evolve beyond efficiency enhancement toward structural equity transformation in clinical research ecosystems. When combined with ethical governance, diverse workforce development, and inclusive eligibility modernization, AI-driven clinical trials can reconcile innovation with justice.